GenMark Diagnostics, Inc. Reports Preliminary Revenue Results for the Fourth Quarter 2015; Provides Revenue Guidance for the Year 2015; Expects First Quarter 2016 Launch of ePlex in Europe and 510(k) Submission to the FDA in the Second Quarter of 2016
The company expects full year 2015 revenue to be $39.4 million, an increase of 29% versus 2014.
The company still expects a first quarter 2016 launch of ePlex in Europe and 510(k) submission to the FDA in the second quarter of 2016.